title: Developments in the surgical management of sporadic synchronous bilateral renal tumours.
abstract: OBJECTIVE
  To examine our experience with managing sporadic bilateral renal masses, focusing on trends in surgical management over time, because as loss of renal function is associated with adverse cardiovascular outcomes, nephron-sparing approaches are increasingly emphasized in the treatment of kidney tumours, creating new challenges for the treatment of bilateral tumours.
  
  
  METHODS
  We identified all patients who underwent partial or radical nephrectomy (PN or RN) at Memorial Sloan-Kettering Cancer Center (MSKCC) during 1989-2008. We compared patients presenting with synchronous bilateral renal masses with those with unilateral tumour and evaluated trends in management using logistic regression.
  
  
  RESULTS
  Of the 2777 patients studied, 73 (3%) presented with synchronous bilateral disease. The overall survival and clinical/pathological features between groups were similar. Of those patients receiving bilateral operations for synchronous tumours, three had bilateral RN (all before 2003), 28 (38%) had an RN followed by a PN, 10 (14%) had a PN then an RN, and 32 (44%) had bilateral PN. Over time, the proportion of patients receiving bilateral PN increased (P < 0.001); 13 of 14 patients after 2005 had bilateral PN, compared with only 34% (16 of 45) between 1995 and 2004. Forty-five patients (62%) had the larger tumour removed during the first operation. The concordance rate between tumours in a specific histological subtype was 70% (51/73), and concordance for benign vs malignant disease was 90% (66/73).
  
  
  CONCLUSIONS
  The use of PN in the management of synchronous bilateral renal masses has increased over time. The contemporary treatment of synchronous bilateral renal masses at MSKCC involves staged PN when feasible, with the more involved kidney (often larger tumour) operated on first.
authors.affiliation: Department of Surgery - Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. lowrancw@mskcc.org
authors.forename: William T
authors.initials: WT
authors.lastname: Lowrance
authors.forename: David S
authors.initials: DS
authors.lastname: Yee
authors.forename: Alexandra C
authors.initials: AC
authors.lastname: Maschino
authors.forename: Angel M
authors.initials: AM
authors.lastname: Cronin
authors.forename: Melanie
authors.initials: M
authors.lastname: Bernstein
authors.forename: R Houston
authors.initials: RH
authors.lastname: Thompson
authors.forename: Paul
authors.initials: P
authors.lastname: Russo
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000601:surgery*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000401:mortality / Q000601:surgery*; D009392:Nephrectomy / Q000401:mortality / Q000639:trends*; D011446:Prospective Studies; D016896:Treatment Outcome